



Condensed Interim Consolidated Financial Statements
Three Months Ended March 31, 2022 and 2021



Three Months Ended March 31, 2022 and 2021

<u>INDEX</u>	<u>Page</u>
Notice of No Auditor Review	3
Condensed Interim Consolidated Financial Statements	
Condensed Interim Consolidated Statements of Financial Position	4
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss	5
Condensed Interim Consolidated Statements of Cash Flows	6
Condensed Interim Consolidated Statements of Changes in Shareholders' Equity	7
Notes to the Condensed Interim Consolidated Financial Statements	8 - 21



NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor Smythe Ratcliffe LLP, Chartered Accountants has not performed a review of these condensed interim consolidated financial statements in accordance with standards established by the Chartered Public Accountants of Canada for a review of interim financial statements by an entity's auditor.

May 27, 2021



Condensed Interim Consolidated Statements of Financial Position (Unaudited)
(Expressed in Canadian Dollars)

As at		March 31, 2022	December 31, 2021
	Note	\$	\$
Assets			
Current			
Cash and cash equivalents	5	1,129,804	218,733
Amounts receivable		96,851	70,212
Prepaid expenses and deposits		20,414	38,826
		1,247,069	327,771
Property and Equipment	6	17,168	18,116
Loan receivable from Just Kush	7	570,455	535,271
Total assets		1,834,692	881,158
Liabilities			
Current			
Accounts payable and accrued liabilities	9	288,186	422,056
Total liabilities		288,186	422,056
Shareholders' Equity			
Share Capital	10	49,438,767	48,368,156
Reserves	10	8,333,450	7,689,723
Deficit		(56,225,711)	(55,598,777)
Total shareholders' equity		1,546,506	459,102
Total liabilities and shareholders' equity		1,834,692	881,158

Approved on behalf of the Board:

"William Rascan"
..... Director
William Rascan

"Steven Feldman"
..... Director
Steven Feldman

The accompanying notes are an integral part of these condensed interim consolidated financial statements.



Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited)
(Expressed in Canadian Dollars)

For the periods ended March 31,		2022	2021
	Note	\$	\$
Expenses			
Accounting, legal and audit		11,074	4,309
Amortization	6	948	456
Consulting fees		120,970	231,860
Management fees		55,500	49,500
Office and general		262,292	5,537
Share-based payments	10	167,943	18,116
Shareholder communications and investor relations		12,403	12,000
Transfer agent and filing fees		9,309	40,402
Research and development costs		21,679	255,269
Loss before Other Items		(662,118)	(617,449)
Interest Income		-	550
Accretion of loan receivable from Just Kush	7	35,184	-
Net Loss and Comprehensive Loss for the Period		(626,934)	(616,899)
Loss and Comprehensive Loss Per Share, Basic and Diluted		(0.01)	(0.01)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted		118,352,782	111,137,867

The accompanying notes are an integral part of these condensed interim consolidated financial statements.



Condensed Interim Consolidated Statements of Cash Flows (Unaudited)
(Expressed in Canadian Dollars)

For the periods ended March 31,		2022	2021
Operating Activities	Note	\$	\$
Net loss for the period		(626,934)	(616,899)
Items not involving cash			
Amortization		948	456
Accretion of loan receivable from Just Kush	7	(35,184)	-
Share-based payments	10	167,943	18,116
Interest accrued on short term investments		-	(550)
Changes in non-cash working capital			
Amounts receivable		(26,639)	(10,235)
Prepaid expenses		18,412	107,880
Accounts payable and accrued liabilities		(70,475)	(128,317)
Cash Used in Operating Activities		(571,929)	(629,549)
Financing Activities			
Shares issued for cash, net of issue costs	10	1,483,000	-
Cash Provided by Financing Activities		1,483,000	-
Net change in cash		911,071	(629,549)
Cash, Beginning of the Period		218,733	2,135,293
Cash, End of the Period		1,129,804	1,505,744

Supplemental Disclosures with Respect to Cash Flows (note 11)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.



Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited)
 Three Months Ended March 31, 2022 and 2021
 (Expressed in Canadian Dollars)

	Note	Number of Shares	Share Capital	Reserves	Deficit	Total
			\$	\$	\$	\$
Balance, December 31, 2020		111,137,867	48,236,392	7,341,282	(52,914,158)	2,663,516
Share-based payments		-	-	18,116	-	18,116
Shares returned to treasury	7	(750,000)	-	-	-	-
Net loss for the period		-	-	-	(616,899)	(616,899)
Balance, March 31, 2021		110,387,867	48,236,392	7,359,398	(53,531,057)	2,064,733
Share-based payments	10	-	-	330,325	-	330,325
Shares issued for settlement of debt	10	1,615,210	131,764	-	-	131,764
Shares returned to treasury	7	(500,000)	-	-	-	-
Net loss for the period		-	-	-	(2,067,720)	(2,067,720)
Balance, December 31, 2021		111,503,077	48,368,156	7,689,723	(55,598,777)	459,102
Private placement	10	29,670,000	1,483,500	-	-	1,483,500
Share issuance cost		-	(500)	-	-	(500)
Share-based payments	10	-	-	167,943	-	167,943
Shares issued for settlement of debt	8	1,056,583	63,395	-	-	63,395
Issuance of warrants	10	-	(475,784)	475,784	-	-
Net loss for the period		-	-	-	(626,934)	(626,934)
Balance, March 31, 2022		142,229,660	49,438,767	8,333,450	(56,225,711)	1,546,506

The accompanying notes are an integral part of these condensed interim consolidated financial statements.



Nova Mentis Life Science Corp.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)
For the periods ended March 31, 2022 and 2021
(Expressed in Canadian Dollars)

1. NATURE OF BUSINESS AND GOING CONCERN

Nova Mentis Life Science Corp. (the "Company") is a company based in Vancouver, British Columbia, and incorporated in the province of British Columbia. The Company is listed on the Canadian Securities Exchange (the "Exchange") under the symbol "NOVA". The Company was previously known as Liberty Leaf Holdings Ltd. and was previously listed on the Canadian Securities Exchange (the "Exchange") under the symbol "LIB". Effective June 26, 2020, the shares of the Company commenced trading on the Canadian Securities Exchange on a consolidated basis under the name "Nova Mentis Life Science Corp." and stock symbol "NOVA". More information regarding the transaction is provided in note 8.

The principal address of the Company is located at 700 – 838 West Hastings Street, Vancouver, British Columbia, Canada, V6C 0A6.

These condensed interim consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations.

Several adverse conditions cast significant doubt on the validity of this assumption. The Company incurred an operating loss during the period ended March 31, 2022 of \$626,934 (March 31, 2021 - \$616,899). As at March 31, 2022, the Company has an accumulated deficit of \$56,225,711 (December 31, 2021 - \$55,598,777), has limited resources, and no sources of operating cash flow. There are no assurances that sufficient funding will be available to continue operations for an extended period of time.

The application of the going concern concept is dependent upon the Company's ability to satisfy its liabilities as they become due and to obtain the necessary financing to fund its subsidiaries or enter into agreements with other medicinal psychedelic-related businesses. Management is actively engaged in the review and due diligence on opportunities of merit in the medicinal psychedelic sector and is seeking to raise the necessary capital to meet its funding requirements. There can be no assurance that management's plan will be successful. If the going concern assumption were not appropriate for these consolidated financial statements, then adjustments may be necessary in the carrying value of assets and liabilities, the reported expenses and the statements of financial position classifications used. Such adjustments could be material.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. While the COVID-19 pandemic has not significantly impacted the Company's operations during 2021, the extent to which COVID-19 may adversely impact the Company's business and financing opportunities going forward will depend on future developments such as the geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing, business closures or business disruptions, and the effectiveness of actions taken in Canada and other countries to contain and treat the disease.

Nova Mentis Life Science Corp.



Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

2. BASIS OF PRESENTATION

a) Statement of compliance

These condensed interim consolidated financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). These condensed Interim Financial Statements have been prepared in accordance with International Accounting Standard 34, *Interim Financial Reporting*. Accordingly, they do not include all of the information required for full interim financial statements required by IFRS as issued by IASB and interpretations issued by IFRIC.

The policies applied in these Interim Financial Statements are based on IFRSs issued and outstanding as of the date of filing this report. The same accounting policies and methods of computation followed in these condensed interim consolidated financial statements are set out in note 3 of the most recently filed annual financial statements as at and for the year ended December 31, 2021, except where noted below. Any subsequent changes to IFRS that are given effect in the Company's annual financial statements for the year ending December 31, 2022 could result in restatement of these Condensed Interim Consolidated Financial Statements.

b) Basis of measurement

These condensed interim consolidated financial statements have been prepared using the historical cost basis, except for certain financial instruments, which are measured at fair value. These condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

c) Principles of consolidation

The condensed interim consolidated financial statements of the Company consolidate the accounts of the Company and its wholly-owned subsidiaries as at March 31, 2022 and 2021:

	Country	Principal Activity	Ownership interest
Nova Mentis Biotech Corp.	Canada	Psilocybin research & development	100%
Pilz Bioscience Corp.	Canada	Psilocybin research & development	100%

A subsidiary is consolidated from the date upon which control is acquired by the Company and all material intercompany transactions and balances have been eliminated on consolidation. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.

d) Approval of the condensed interim consolidated financial statements

The condensed interim consolidated financial statements of the Company for the period ended March 31, 2022 were approved and authorized for issue by the Board of Directors on May 27, 2022.

Nova Mentis Life Science Corp.



Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

e) Use of estimates and judgments

The preparation of these condensed interim consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities at the date of the condensed interim consolidated financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and may affect both the period of revision and future periods.

The key areas of judgment applied in the preparation of the condensed interim consolidated financial statements that could result in a material adjustment to the carrying amounts of assets and liabilities is as follows:

- Research and development expenditures

Costs to develop products that will be sold are capitalized to the extent that the criteria for recognition as intangible assets in IAS 38 Intangible Assets are met. Those criteria require that the product is technically, and economically feasible, which management assessed based on the attributes of the development project, perceived user needs, industry trends and expected future economic conditions. Management considers these factors in aggregate and applies significant judgment to determine whether the product is feasible. The Company has not capitalized any product development costs as at March 31, 2022 and 2020.

- Going concern

The assessment of the Company's ability to continue as a going concern and to raise sufficient funds to pay for its ongoing operating expenses, meet its liabilities for the ensuing year, and to fund planned and contractual exploration programs, involves significant judgment based on historical experience and other factors including expectation of future events that are believed to be reasonable under the circumstances.

- Significant influence

Where the Company holds a significant shareholding in an investment and has the power to exercise significant influence through common officers and board members, such an investment is treated as an associate. Management applies judgment to determine when the Company loses significant influence over an investee by assessing whether it has lost the power to participate in the financial and operating policy decisions of that investee.

- Determination of control in business acquisitions

The determination of the acquirer in business acquisitions is subject to judgment and requires the Company to determine which party obtains control of the combining entities. Management applies judgment in determining control by assessing the following three factors: whether the Company has power; whether the Company has exposure or rights to variable returns; and whether the Company has the ability to use its power to affect the amount of its returns. In exercising this judgment, management reviewed the representation on the Board of Directors and key management personnel, the party that initiated the transaction, and each of the entities' activities.

Nova Mentis Life Science Corp.



Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

The assessment of whether an acquisition constitutes a business is also subject to judgment and requires the Company to review whether the acquired entity contains all three elements of a business, including inputs, processes and the ability to create output. Management has had to apply judgments relating to the asset purchase transaction with the acquisitions of Nova Biotech and Pilz with respect to whether the acquisition was a business combination or an asset acquisition. See Notes 8 and 9 of the Company's Annual Consolidated Financial Statements for the years ended December 31, 2021 and 2020.

The key estimates applied in the preparation of the condensed interim consolidated financial statements that could result in a material adjustment to the carrying amounts of assets and liabilities are as follows:

- The inputs used in assessing the recoverable amount of deferred tax assets

The Company estimates the expected manner and timing of the realization or settlement of the carrying value of its assets and liabilities and applies the tax rates that are enacted or substantively enacted on the estimated dates of realization or settlement.

- Share-based payments

The value of share-based payments is subject to the limitations of the Black-Scholes option pricing model that incorporates market data and involves uncertainty in estimates used by management in the assumptions. Because the Black-Scholes option pricing model requires the input of highly subjective assumptions, including the volatility of share prices, changes in subjective input assumptions can materially affect the fair value estimate.

- Fair value of equity issuances for non-cash consideration

In instances where the fair value of assets received, or services rendered cannot be reliably measured management estimates the fair value of common shares issued as non-cash consideration by reference to the closing trading price of its shares in active markets. In instances where common shares issued are subject to internally imposed hold periods, management applies a discount to the value of the shares. A discount rate of 4.8% was applied to certain shares issued in accordance with the acquisition of Pilz which were subject to a voluntary pooling agreement.

- Fair value of investment in Just Kush Enterprises Ltd.

The Company determined the fair value of its interest in its investment in Just Kush on the date that significant influence was lost. The determination of fair value requires management to make estimates regarding the future cash flows expected to flow to the entity from its investment.

Actual results could differ from those estimates. Key judgments and estimates made by management with respect to those areas noted previously have been disclosed in the notes to the consolidated financial statements, as appropriate.

- Loan receivable from Just Kush Enterprises Ltd.

The loan is recorded at the estimated recoverable amount. Management applies judgment in estimating the recoverable amount as well as the timing of receipt of cash.

Management also uses estimation in determining the effective interest rate used to measure the loan. Management applies judgment in determining an appropriate discount rate based on the debtor's credit worthiness.

Nova Mentis Life Science Corp.



Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies have been applied by the Company consistently throughout the period for purposes of these condensed interim consolidated financial statements. Additional details regarding Nova's accounting policies, the critical judgments, estimates and assumptions, and how they are applied in the preparation of these condensed interim consolidated financial statements, are reflected in note 3 of the Company's Annual Financial Statements for the years ended December 31, 2021 and 2020.

- Adoption of new accounting standards

IAS 16 – Property, Plant and Equipment ("IAS 16") was amended. The amendments introduce new guidance, such that the proceeds from selling items before the related property, plant and equipment is available for its intended use can no longer be deducted from the cost. Instead, such proceeds are to be recognized in profit or loss, together with the costs of producing those items. The amendments are effective for annual periods beginning on January 1, 2022.

IAS 37 – Provisions, Contingent Liabilities, and Contingent Assets ("IAS 37") was amended. The amendments clarify that when assessing if a contract is onerous, the cost of fulfilling the contract includes all costs that relate directly to the contract – i.e. a full-cost approach. Such costs include both the incremental costs of the contract (i.e. costs a company would avoid if it did not have the contract) and an allocation of other direct costs incurred on activities required to fulfill the contract – e.g. contract management and supervision, or depreciation of equipment used in fulfilling the contract. The amendments are effective for annual periods beginning on January 1, 2022.

The Company has adopted these new standards and has determined there was no significant impact on the condensed interim consolidated financial statements.

- Standards, amendments and interpretations issued and effective for the year ended December 31, 2022

The Company will be required to adopt the following standards and amendments issued by the IASB as described below.

IAS 1 – Presentation of Financial Statements ("IAS 1") was amended in January 2020 to provide a more general approach to the classification of liabilities under IAS 1 based on the contractual arrangements in place at the reporting date. The amendments clarify that the classification of liabilities as current or noncurrent is based solely on a company's right to defer settlement at the reporting date. The right needs to be unconditional and must have substance. The amendments also clarify that the transfer of a company's own equity instruments is regarded as settlement of a liability, unless it results from the exercise of a conversion option meeting the definition of an equity instrument. The amendments are effective for annual periods beginning on January 1, 2023.

IFRS 10 – Consolidated Financial Statements ("IFRS 10") and IAS 28 – Investments in Associates and Joint Ventures ("IAS 28") were amended in September 2014 to address a conflict between the requirements of IAS 28 and IFRS 10 and clarify that in a transaction involving an associate or joint venture, the extent of gain or



Nova Mentis Life Science Corp.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

loss recognition depends on whether the assets sold or contributed constitute a business. The effective date of these amendments is yet to be determined; however early adoption is permitted.

IFRS 17 – Insurance Contracts (“IFRS 17”) is a new standard that requires insurance liabilities to be measured at a current fulfillment value and provides a more uniform measurement and presentation approach for all insurance contracts. These requirements are designed to achieve the goal of a consistent, principle-based accounting for insurance contracts. IFRS 17 supersedes IFRS 4, Insurance Contracts, and related interpretations.

The Company is currently assessing the impact of these standards.

4. RESTATEMENT

During the year ended December 31, 2021, the Company became aware of errors in discounting the Loan Receivable from Just Kush and the purchase allocation in the acquisition of Pilz Bioscience Corp. resulting in a restatement of the previously issued consolidated financial statements for the year ended December 31, 2020. The errors caused an overstatement of the loan receivable from Just Kush of \$1,595,626, an overstatement of prepaid assets of \$450,000, an overstatement of share capital of \$61,924 and an understatement of net loss and comprehensive loss of \$1,983,702.

The following tables outline the effect of the changes made to the consolidated financial statements originally filed.

Impact on the consolidated statement of financial position as at December 31, 2021:

	Previously Reported	Change	Restated
	\$	\$	\$
Prepaid assets	867,821	(450,000)	417,821
Loan receivable from Just Kush	2,037,839	(1,595,626)	442,213
Total Assets	5,092,105	(2,045,627)	3,046,478
Share capital	48,298,316	(61,924)	48,236,392
Deficit	(50,930,456)	(1,983,702)	(52,914,158)
Total shareholders' equity	4,709,142	(2,045,626)	2,663,516
Total liabilities and shareholders' equity	5,092,105	(2,045,626)	3,046,478

Nova Mentis Life Science Corp.



Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

Impact on the consolidated statement of loss and comprehensive loss for the year ended December 31, 2020:

	Previously Reported	Change	Restated
	\$	\$	\$
Impairment of investment in Just Kush	(4,071,263)	(1,595,626)	(5,666,889)
Consideration paid in excess of net assets acquired from Pilz	(11,105,319)	(388,076)	(11,493,395)
Net Loss and Comprehensive Loss for the Year	(23,248,988)	(1,983,702)	(25,232,690)
Loss and Comprehensive Loss Per Share, Basic and Diluted	(0.45)	(0.04)	(0.49)

All adjustments affected only non-cash items; therefore, there was no impact to cash provided by operating activities and also no impact to cash used in investing activities or cash provided by financing activities.

The restatement had no impact on the consolidated statement of financial position as at January 1, 2020.

5. CASH AND CASH EQUIVALENTS

On March 31, 2022, cash and cash equivalents include \$1,129,804 (December 31, 2021 - \$218,733) in the operating bank accounts held with major Canadian financial institutions.

6. FINANCIAL INSTRUMENTS

The Company has exposure to the following risks from its use of financial instruments:

- Credit risk;
- Liquidity risk; and
- Market risk.

a) Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company manages credit risk, in respect of cash and cash equivalents, by placing cash with major Canadian financial institutions. As at March 31, 2022, the Company is therefore exposed to credit risk with respect to cash and cash equivalents of \$1,129,804 (December 31, 2021 - \$218,733). Furthermore, the Company is exposed to credit risk associated with the Loan Receivable from Just Kush. Management assesses the credit worthiness of entities it advances loans to prior to and on a periodic basis. If it is determined that the counterparty is undergoing financial difficulty management estimates a recoverable amount and books an allowance for expected credit losses.

b) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company's approach to managing liquidity risk is to ensure, as far as possible, that it will always have sufficient liquid funds to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. As of March 31, 2022, the



Nova Mentis Life Science Corp.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

Company has cash and cash equivalents of \$1,129,804 (December 31, 2021 - \$218,733) to meet contractual financial liabilities of \$288,186 (December 31, 2021 - \$422,056). All of the liabilities presented as accounts payable and accrued liabilities are due within 90 days of March 31, 2022.

c) Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates, will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposure within acceptable parameters, while optimizing the return on capital.

As at March 31, 2022, management considers the Company's market risk to be low as it held no short-term investments at the period end date (December 31, 2021 - \$nil).

6. PROPERTY AND EQUIPMENT

	Computer Equipment	Office Equipment	Total
Cost	\$	\$	\$
Balance, December 31, 2020	16,173	39,880	56,053
Additions	-	-	-
Balance, December 31, 2021	16,173	39,880	56,053
Additions	-	-	-
Balance, March 31, 2022	16,173	39,880	56,053
Accumulated Amortization			
Balance, December 31, 2020	15,102	17,837	32,939
Amortization	589	4,409	4,998
Balance, December 31, 2021	15,691	22,246	37,937
Amortization	66	882	948
Balance, March 31, 2022	15,757	23,128	38,885
Net Book Value			
Net Book Value, December 31, 2021	482	17,634	18,116
Net Book Value, March 31, 2022	416	16,752	17,168

7. LOAN RECEIVABLE FROM JUST KUSH

On December 6, 2017, the Company signed an agreement to acquire shares of Just Kush Enterprises Ltd. ("Just Kush"), a private British Columbia company with an in process ACMPR license.

Pursuant to the agreement, the Company had advanced payment to Just Kush and the amount pertains to the build out expenditures incurred at the Just Kush facility to further Just Kush's ACMPR application. These amounts have been paid by the Company and are owed to the Company by Just Kush. During the year ended December 31, 2020, the Company advanced \$434,421 to Just Kush.



Nova Mentis Life Science Corp.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

Due to deteriorating market conditions in the cannabis industry and a general disagreement between the stakeholders involved regarding terms of the original purchase agreement and whether the Company had an obligation to contribute capital to Just Kush, the Company entered into a rescission agreement dated March 19, 2021 with Just Kush such that the original purchase agreement is null and void.

Concurrent with the rescission agreement, the Company entered into a loan agreement whereby Just Kush has agreed to repay a principal sum of \$2,037,839 representing advances made by the Company to Just Kush in addition to the cash consideration of the original purchase agreement. Terms of the loan are as follows:

Just Kush shall repay the principal amount on or before March 30, 2027 in monthly installments commencing on March 30, 2022, of the greater of \$15,000 or 10% of the borrower's gross revenue for the immediately preceding calendar month. The loan does not accrue interest. As at March 31, 2022, and up to the date of filing these interim financial statements, the Company had not received its first monthly installment against the loan receivable. In the event that on or before March 30, 2026, the borrower has repaid an aggregate of \$800,000 of the principle, the Company shall forgive the remaining balance on the loan to Just Kush.

As at March 31, 2022, the fair value of the loan based on the principal sum of \$2,037,839, and using an effective interest rate of 29%, was \$570,455 (December 31, 2021 – \$535,271). During the three months ended March 31, 2022, the Company recognized accretion on the loan receivable of \$35,184 (2021 – \$nil).

In accordance with the rescission agreement, shares involved in the original purchase agreement were returned to capital: 750,000 escrow shares were returned to capital on March 31, 2021, and 500,000 shares were returned to capital on April 21, 2021.

Continuity of the loan receivable from Just Kush is as follows:

	\$
Balance, December 31, 2020	442,213
Accretion	93,058
Balance, December 31, 2021	535,271
Accretion	35,184
Balance, March 31, 2022	570,455

8. DEBT SETTLEMENT

On January 13, 2022, the Company has entered into a debt settlement agreement pursuant to which the Company has agreed to issue 1,056,583 common shares (each, a "Share"), at a deemed price of \$0.06 per Share, to settle indebtedness of \$63,395 (the "Transaction"). All Shares issued pursuant to the Transaction are subject to a statutory four-month and one-day hold period from the date of issue.

Nova Mentis Life Science Corp.



Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

9. RELATED PARTY TRANSACTIONS

These amounts of key management compensation and other related party transactions are included in the amounts shown on the consolidated statements of comprehensive loss for the periods ended March 31, 2022 and 2021:

	2022	2021
	\$	\$
Consulting fees	30,000	18,000
Management fees	55,500	49,500
Shareholder communications	7,500	12,000

These transactions were in the normal course of operations. During the period ended March 31, 2022, the Company engaged:

- The Chief Executive Officer (“CEO”), to provide management services to the Company in consideration of \$37,500 (2021 - \$37,500);
- The Chief Financial Officer (“CFO”), to provide management services in consideration of \$18,000 (2021 - \$12,000);
- The Chief Operating Officer (“COO”), to provide consulting services to the Company in consideration of \$30,000 (2021 - \$18,000);
- A director to provide shareholder communication services for consideration of \$7,500 (2021 - \$12,000); and
- Directors to provide consulting services for consideration of \$Nil (2021 - \$18,000).

As at March 31, 2022, accounts payable and accrued liabilities included \$9,568 (December 31, 2021 - \$23,929) due to officers and directors or companies controlled by current or former officers and directors. The amounts due are non-interest-bearing, unsecured, and without stated terms of repayment.

10. SHARE CAPITAL

Authorized share capital

Unlimited number of common shares without par value.

a) Issued share capital

During the period ended March 31, 2022

On January 13, 2022, the Company issued 1,056,583 common shares in settlement of debt to a consultant of the Company. These shares were fair valued at \$0.06 to settle \$63,395 in debt (Note 8).

On March 15, 2022, the Company announced the closing of a non-brokered private placement through the issuance of 29,670,000 units at \$0.05 per unit for total gross proceeds of \$1,483,500 (the “Placement”). Each unit is comprised of one common share of the capital of the Company and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at a price of \$0.075 for a period of 18 months from the date of issue. The common shares are subject to a statutory 4-month hold



Nova Mentis Life Science Corp.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

period. Insiders and parties related to the Company subscribed for 2,550,000 units for gross proceeds of \$127,500.

During the year ended December 31, 2021

The Company rescinded its agreement with Just Kush as detailed in note 7. As a result of that rescission, on March 31, 2021, 750,000 escrow shares were cancelled, and on April 21, 2021, 500,000 common shares were returned to treasury.

On June 10, 2021, the Company issued 1,513,306 common shares in settlement of debt to a consultant. These shares were fair valued at \$0.08 to settle \$121,064 in debt.

On August 24, 2021, the Company issued 101,904 common shares in settlement of debt to a Director of the Company. These shares were fair valued at \$0.105 to settle \$10,700 in debt.

b) Warrants

On March 15, 2022, the Company issued 29,670,000 warrants in connection with a non-brokered private placement (See note 10a). Each warrant entitles the holder to purchase one common share at a price of \$0.075 per share for a period of 18 months from the date of issue. The Company applied the fair value method using the Black-Scholes pricing model in accounting for warrants issued with the following weighted-average assumptions: risk-free interest rate of 1.77%; expected dividend yield of zero; expected share price volatility of 125%; and expected life of 1.5 years. The Company used historical volatility to estimate the volatility of the share price. The fair value assigned to these warrants was \$475,784.

Warrant transactions and the number of warrants outstanding are summarized as follows:

	Number of Warrants	Weighted Average Exercise Price \$
Balance, December 31, 2020 and 2021	-	-
Issued	29,670,000	0.075
Balance, March 31, 2022	29,670,000	0.075

The following warrants were outstanding as at March 31, 2022:

Expiry Date	Exercise Price \$	Number of Warrants Outstanding	Weighted Average Remaining Life (yrs)
September 15, 2023	0.075	29,670,000	1.46
	0.075	29,670,000	

c) Share options

The Company has adopted a share option plan pursuant to which the Board of Directors of the Company may, from time to time, in its discretion, and in accordance with the Exchange requirements, grant to

Nova Mentis Life Science Corp.



Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

directors, officers, employees and consultants of the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares at the time of grant and the options are exercisable for a period not to exceed 10 years from the date of grant. The number of common shares reserved for issuance to any individual director or officer will not exceed 5% of the issued and outstanding common shares and the number of common shares reserved for issuance to all technical consultants will not exceed 2% of the issued and outstanding common shares. Options may be exercised within 90 days following cessation of the optionee's position with the Company, provided that if the cessation of office, directorship, employment or consulting arrangement was by reason of death, the option may be exercised within a maximum period of one year after such death, subject to the expiry date of such option.

Options granted to directors, employees and consultants vest immediately. Options granted to consultants engaged in investor relations activities will vest in stages over a minimum period of 12 months with no more than one-quarter of the options vesting in any three-month period.

Share option transactions and the number of share options outstanding and exercisable are summarized as follows:

	Number of Options	Weighted Average Exercise Price \$
Balance at December 31, 2020	6,800,000	0.23
Granted	3,575,000	0.12
Expired	(1,900,000)	0.27
Balance at December 31, 2021	8,475,000	\$ 0.17
Granted	1,250,000	0.08
Expired	(700,000)	0.17
Balance at March 31, 2022	9,025,000	\$ 0.16

During the period ended March 31, 2022

On March 22, 2022, 1,250,000 options were granted to consultants of the Company. The options have an exercise price of \$0.08 and expire one year from the date of grant. The Company applied the fair value method using the Black-Scholes option pricing model in accounting for its share options granted with the following weighted-average assumptions: risk-free interest rate of 0.18%; expected dividend yield of zero; expected share price volatility of 111%; and expected life of 2 years. The Company used historical volatility to estimate the volatility of the share price. The weighted average grant date fair value of each option was \$0.08. Accordingly, \$42,693 was recognized as share-based payment expense during the three months ended March 31, 2022.

During the period ended March 31, 2022, 700,000 options expired unexercised.



Nova Mentis Life Science Corp.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

During the period ended March 31, 2021

The Company applied the fair value method using the Black-Scholes option pricing model in accounting for its share options granted with the following weighted-average assumptions: risk-free interest rate of 0.18%; expected dividend yield of zero; expected share price volatility of 170%; and expected life of 2 years. The Company used historical volatility to estimate the volatility of the share price. The weighted average grant date fair value of each option was \$0.17. Accordingly, \$18,116 was recognized as share-based payment expense during the three months ended March 31, 2021.

The following share options were outstanding and exercisable as at March 31, 2022:

Expiry Dates	Exercise Price \$	Weighted Average Remaining Life (yrs)	Number of Options Outstanding	Number of Options Exercisable
September 17, 2022	0.20	0.47	2,050,000	2,050,000
November 6, 2022	0.20	0.60	1,800,000	1,800,000
December 1, 2022	0.265	0.67	200,000	200,000
December 11, 2022	0.30	0.70	200,000	200,000
February 10, 2023	0.235	0.87	100,000	100,000
March 8, 2023	0.20	0.94	25,000	25,000
March 14, 2023	0.08	0.98	1,250,000	1,250,000
July 14, 2023	0.12	1.29	950,000	950,000
August 17, 2023	0.14	1.38	100,000	100,000
December 17, 2023	0.29	1.72	200,000	200,000
October 22, 2024	0.09	2.56	250,000	250,000
July 14, 2026	0.12	4.29	1,900,000	1,900,000
	0.16	1.83	9,025,000	9,025,000

d) Restricted Share Units

On January 11, 2022, the Company granted 2,350,000 Restricted Share Units ("RSUs") to directors, officers, and consultants of the Company. The RSUs expire 24 months from the date of grant. The RSUs are governed by the Company's RSU Plan, which was approved by the Company's shareholders on December 22, 2020.

The total fair value of the RSUs on the date of grant was \$141,000, which is based on the market price of the Company's shares on the date of grant. RSUs granted to directors and officers vested immediately, while RSUs granted to certain consultants of the Company will vest at 50% on July 11, 2022, and 50% on January 11, 2023.

Nova recognized \$125,250 in share-based payments on the Statement of loss and comprehensive loss during the three months ended March 31, 2022 (2021 – \$nil) for RSUs that vested during the period then-ended.

Nova Mentis Life Science Corp.



Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)

For the periods ended March 31, 2022 and 2021

(Expressed in Canadian Dollars)

11. SUPPLEMENTAL DISCLOSURES WITH RESPECT TO CASH FLOWS

For the periods ended March 31,	2022	2021
	\$	\$
Shares issued for settlement of debt	63,395	-

12. SEGMENTED DISCLOSURE AND SUBSIDIARIES

The Company currently operates in one industry segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly-owned subsidiaries, Nova Mentis Biotech Corp., and Pilz Bioscience Corp. All of the Company's long-term assets are located in Canada.

13. CAPITAL MANAGEMENT

The Company considers its capital to be comprised of shareholders' equity.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares. Although the Company has been successful at raising funds in the past through the issuance of share capital, it is uncertain whether it will continue this method of financing due to the current difficult market conditions.

In order to facilitate the management of its capital requirements, the Company prepares expenditure budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions.

Management reviews the capital structure on a regular basis to ensure that the above objectives are met. There have been no changes to the Company's approach to capital management during the period ended March 31, 2022. The Company is not subject to external restrictions on its capital.

14. SUBSEQUENT EVENTS

- a) Subsequent to the three months ended March 31, 2022, 200,000 options were granted to a consultant of the Company. The options have an exercise price of \$0.085 and expire 2 years from the date of grant.